NYSEAMERICAN:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $3.55 -0.09 (-2.47%) Closing price 04:10 PM EasternExtended Trading$3.57 +0.02 (+0.45%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Perspective Therapeutics Stock (NYSEAMERICAN:CATX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CATX alerts:Sign Up Key Stats Today's Range$3.50▼$3.7050-Day Range$3.04▼$3.9852-Week Range$1.60▼$13.44Volume802,422 shsAverage Volume790,017 shsMarket Capitalization$263.62 millionP/E RatioN/ADividend YieldN/APrice Target$12.56Consensus RatingBuy Company Overview Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. Read More Perspective Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCATX MarketRank™: Perspective Therapeutics scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingBuy Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialPerspective Therapeutics has a consensus price target of $12.56, representing about 253.7% upside from its current price of $3.55.Amount of Analyst CoveragePerspective Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Perspective Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.20) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Perspective Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.98% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 4.71%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.98% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 4.71%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment0.22 News SentimentPerspective Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Perspective Therapeutics this week, compared to 5 articles on an average week.Search Interest26 people have searched for CATX on MarketBeat in the last 30 days. This is an increase of 550% compared to the previous 30 days.MarketBeat Follows7 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.72% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CATX Stock News HeadlinesPerspective Therapeutics (NYSE:CATX) Given Buy Rating at HC WainwrightOctober 5 at 2:35 AM | americanbankingnews.comHC Wainwright & Co. Reiterates Perspective Therapeutics (CATX) Buy RecommendationOctober 3 at 4:43 PM | msn.comElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. Don’t miss your chance.October 6 at 2:00 AM | Angel Publishing (Ad)Perspective Therapeutics' (CATX) Outperform Rating Reaffirmed at WedbushOctober 3 at 2:46 AM | americanbankingnews.comPerspective Therapeutics announces first patient treated with PSV359October 2, 2025 | msn.comPerspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid TumorsOctober 2, 2025 | finance.yahoo.comReviewing Perspective Therapeutics (NYSE:CATX) & Medifocus (OTCMKTS:MDFZF)September 29, 2025 | americanbankingnews.comOppenheimer more confident Perspective’s VMT update will build on prior resultsSeptember 16, 2025 | msn.comSee More Headlines CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $3.19 at the beginning of 2025. Since then, CATX stock has increased by 11.3% and is now trading at $3.55. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.21). The business earned $0.37 million during the quarter. Perspective Therapeutics had a negative trailing twelve-month return on equity of 27.40% and a negative net margin of 4,096.66%. When did Perspective Therapeutics' stock split? Perspective Therapeutics's stock reverse split on Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2024Today10/06/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:CATX Previous SymbolNYSE:CATX CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Price Target for Perspective Therapeutics$12.56 High Price Target$20.00 Low Price Target$5.00 Potential Upside/Downside+257.2%Consensus RatingBuy Rating Score (0-4)3.18 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.51 million Net Margins-4,096.66% Pretax Margin-3,780.02% Return on Equity-27.40% Return on Assets-23.16% Debt Debt-to-Equity RatioN/A Current Ratio9.60 Quick Ratio9.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book1.32Miscellaneous Outstanding Shares74,263,000Free Float65,209,000Market Cap$261.03 million OptionableOptionable Beta1.14 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSEAMERICAN:CATX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.